Kadin ME - Search Results

1

Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas.

Maliniemi P, Laukkanen K, Väkevä L, Dettmer K, Lipsanen T, Jeskanen L, Bessede A, Oefner PJ, Kadin ME, Ranki A. Maliniemi P, et al. Among authors: kadin me. Oncoimmunology. 2017 Feb 10;6(3):e1273310. doi: 10.1080/2162402X.2016.1273310. eCollection 2017. Oncoimmunology. 2017. PMID: 28405495 Free PMC article.

2

CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression.

Mori M, Manuelli C, Pimpinelli N, Mavilia C, Maggi E, Santucci M, Bianchi B, Cappugi P, Giannotti B, Kadin ME. Mori M, et al. Among authors: kadin me. Blood. 1999 Nov 1;94(9):3077-83. Blood. 1999. PMID: 10556192 Free article.

3

Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders.

Kadin ME. Kadin ME. Oncology (Williston Park). 2009 Nov 30;23(13):1158-64. Oncology (Williston Park). 2009. PMID: 20043465 Free article. Review.

4

High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides.

Kadin ME, Pavlov IY, Delgado JC, Vonderheid EC. Kadin ME, et al. J Invest Dermatol. 2012 Mar;132(3 Pt 1):703-10. doi: 10.1038/jid.2011.351. Epub 2011 Nov 10. J Invest Dermatol. 2012. PMID: 22071475 Free PMC article.

5

Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function.

Wolk K, Mitsui H, Witte K, Gellrich S, Gulati N, Humme D, Witte E, Gonsior M, Beyer M, Kadin ME, Volk HD, Krueger JG, Sterry W, Sabat R. Wolk K, et al. Among authors: kadin me. Clin Cancer Res. 2014 Nov 1;20(21):5507-16. doi: 10.1158/1078-0432.CCR-14-0707. Epub 2014 Sep 11. Clin Cancer Res. 2014. PMID: 25212608

6

Intrahepatic Xenograft of Cutaneous T-Cell Lymphoma Cell Lines: A Useful Model for Rapid Biological and Therapeutic Evaluation.

Andrique L, Poglio S, Prochazkova-Carlotti M, Kadin ME, Giese A, Idrissi Y, Beylot-Barry M, Merlio JP, Chevret E. Andrique L, et al. Among authors: kadin me. Am J Pathol. 2016 Jul;186(7):1775-1785. doi: 10.1016/j.ajpath.2016.03.012. Epub 2016 May 13. Am J Pathol. 2016. PMID: 27181405 Free article.

7

Primary cutaneous anaplastic large cell lymphoma with intralymphatic involvement associated with chronic lymphedema.

Fan P, Nong L, Sun J, Liu X, Kadin ME, Li T, Tu P, Wang Y. Fan P, et al. Among authors: kadin me. J Cutan Pathol. 2017 Jul;44(7):616-619. doi: 10.1111/cup.12933. Epub 2017 May 5. J Cutan Pathol. 2017. PMID: 28337783

8

Differential SATB1 Expression Reveals Heterogeneity of Cutaneous T-Cell Lymphoma.

Gao Y, Liu F, Sun J, Wen Y, Tu P, Kadin ME, Wang Y. Gao Y, et al. Among authors: kadin me. J Invest Dermatol. 2021 Mar;141(3):607-618.e6. doi: 10.1016/j.jid.2020.05.120. Epub 2020 Aug 7. J Invest Dermatol. 2021. PMID: 32771472 Free article.

9

SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21.

Wang Y, Gu X, Zhang G, Wang L, Wang T, Zhao Y, Zhang X, Zhou Y, Kadin M, Tu P. Wang Y, et al. Blood. 2014 May 29;123(22):3452-61. doi: 10.1182/blood-2013-10-534693. Epub 2014 Apr 18. Blood. 2014. PMID: 24747435 Free article.

10

KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.

Battistella M, Janin A, Jean-Louis F, Collomb C, Leboeuf C, Sicard H, Bonnafous C, Dujardin A, Ram-Wolff C, Kadin ME, Bensussan A, Bagot M, Michel L. Battistella M, et al. Among authors: kadin me. Br J Dermatol. 2016 Aug;175(2):325-33. doi: 10.1111/bjd.14626. Epub 2016 Jul 13. Br J Dermatol. 2016. PMID: 27037558

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters